Purple Biotech Ltd. (PPBT)
NASDAQ: PPBT · IEX Real-Time Price · USD
0.821
+0.121 (17.37%)
At close: Feb 29, 2024, 3:59 PM
0.850
+0.029 (3.53%)
After-hours: Feb 29, 2024, 5:34 PM EST

Purple Biotech Stock Forecast

PPBT's stock price has decreased by -61.25% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Purple Biotech stock have an average target of 9.67, with a low estimate of 8.00 and a high estimate of 11. The average target predicts an increase of 1,077.83% from the current stock price of 0.82.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $8.00 $9.67 $10 $11
Change +874.42% +1077.8% +1118.0% +1239.8%

Analyst Ratings

The average analyst rating for Purple Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Sep '23Oct '23Nov '23Dec '23Jan '24Feb '24
Strong Buy 333333
Buy 000000
Hold 000000
Sell 000000
Strong Sell 000000
Total 333333

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$10
Strong Buy Reiterates $10 +1,118.03% Feb 27, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$9$10
Strong Buy Maintains $9$10 +1,118.03% Nov 21, 2023
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$7$9
Strong Buy Maintains $7$9 +996.22% Aug 31, 2023
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$7$9
Strong Buy Maintains $7$9 +996.22% Aug 30, 2023
JonesTrading
JonesTrading
Strong Buy
Initiates
$8
Strong Buy Initiates $8 +874.42% Jul 21, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.